Indeed, probably because ‘BRCAness’ and cisplatin cause genome instability of cancer cells, PARP inhibitors were occasionally applied to treat cisplatin-sensitive cancers irrespective of ‘BRCAness’ [44,45]. This evidence concerns the gene PARP1 and cancer.